Lisata Therapeutics Inc (LSTA) has a current Price-to-Book (P/B) ratio of 0.99. Compared to its 3-year average P/B ratio of 0.66, the current P/B ratio is approximately 50.61% higher. Relative to its 5-year average P/B ratio of 0.62, the current P/B ratio is about 59.80% higher. Lisata Therapeutics Inc (LSTA) has a Forward Free Cash Flow (FCF) yield of approximately -99.81%. Compared to its 3-year average FCF yield of -88.02%, the current FCF yield is approximately 13.40% lower. Relative to its 5-year average FCF yield of -71.11%, the current FCF yield is about 40.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LSTA competitors is 328.49, providing a benchmark for relative valuation. Lisata Therapeutics Inc Corp (LSTA.O) exhibits a P/S ratio of 1964.62, which is 498.07% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LSTA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LSTA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LSTA currently overvalued or undervalued?

What is Lisata Therapeutics Inc (LSTA) fair value?

LSTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lisata Therapeutics Inc (LSTA) is between to according to relative valuation method.

How does LSTA's valuation metrics compare to the industry average?

The average P/S ratio for LSTA's competitors is 328.49, providing a benchmark for relative valuation. Lisata Therapeutics Inc Corp (LSTA) exhibits a P/S ratio of 1964.62, which is 498.07% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Lisata Therapeutics Inc (LSTA) as of Mar 02 2026?

As of Mar 02 2026, Lisata Therapeutics Inc (LSTA) has a P/B ratio of 0.99. This indicates that the market values LSTA at 0.99 times its book value.

What is the current FCF Yield for Lisata Therapeutics Inc (LSTA) as of Mar 02 2026?

As of Mar 02 2026, Lisata Therapeutics Inc (LSTA) has a FCF Yield of -99.81%. This means that for every dollar of Lisata Therapeutics Inc's market capitalization, the company generates -99.81 cents in free cash flow.

What is the current Forward P/E ratio for Lisata Therapeutics Inc (LSTA) as of Mar 02 2026?

As of Mar 02 2026, Lisata Therapeutics Inc (LSTA) has a Forward P/E ratio of -1.50. This means the market is willing to pay $-1.50 for every dollar of Lisata Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lisata Therapeutics Inc (LSTA) as of Mar 02 2026?

As of Mar 02 2026, Lisata Therapeutics Inc (LSTA) has a Forward P/S ratio of 1964.62. This means the market is valuing LSTA at $1964.62 for every dollar of expected revenue over the next 12 months.

LSTA Valuation